It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

In a groundbreaking study, scientists from China have successfully created mice with two biological fathers. Though the ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

A revolutionary gene therapy treatment costing a staggering £1.65 million has been approved for NHS use, offering patients ...

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.